EGFR and large cell neuroendocrine carcinoma: Some cases of LCNEC carrying EGFR gene activation mutations have been reported to have good efficacy against EGFR-tyrosine kinase inhibitors (TKIs) (71–75), and ALK inhibitors have also been effective in treating LCNEC cases carrying ALK rearrangements (76).